This clinical trial is focused on studying the effects of different treatment strategies for patients diagnosed with schizophrenia spectrum disorder. This includes conditions such as schizophrenia, schizophreniform disorder, schizoaffective disorder, or brief psychotic episodes. The study will compare two approaches: reducing the dose of antipsychotic medications or maintaining the current treatment. The medications involved in this study include haloperidol decanoate, risperidone, amisulpride (also known as APD421), loxapine succinate, flupentixol decanoate, pregabalin, chlorpromazine hydrochloride (also known as aminazine), levomepromazine hydrochloride, aripiprazole, pipotiazine palmitate, and fluoxetine hydrochloride.
The purpose of the study is to determine if there is a difference in the effectiveness of these two treatment strategies based on the type of psychotic symptoms a patient experiences. The study will last for up to 24 months, during which patients will be monitored to see how well they function in their daily lives. This will be assessed using a scale called the Personal and Social Performance Scale (PSP). Patients will have regular check-ins with their healthcare providers and a specialized evaluation team to track their progress.
Throughout the study, various aspects of the patients’ health will be monitored, including any side effects from the medications, their overall well-being, and their quality of life. The study aims to provide insights into how personalized treatment plans can improve outcomes for individuals with schizophrenia spectrum disorders. The ultimate goal is to find the most effective way to manage these conditions while minimizing side effects and improving patients’ quality of life.



France